Terada Tatsuhiro, Kubota Manabu, Miyata Jun, Obi Tomokazu, Takashima Hirotsugu, Matsudaira Takashi, Bunai Tomoyasu, Ouchi Yasuomi, Murai Toshiya
Department of Neurology, Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan; Department of Biofunctional Imaging, Preeminent Bioimaging Research, Institute of Photonics Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama Higashi-ku, Hamamatsu 431-3192, Japan.
Department of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Brain Disorder Translational Research Group, Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
J Neurol Sci. 2024 Dec 15;467:123327. doi: 10.1016/j.jns.2024.123327. Epub 2024 Nov 23.
The Frontal Assessment Battery (FAB) is widely used to assess executive dysfunction in patients with amnestic mild cognitive impairments due to Alzheimer's disease (aMCI-AD), but its neurobiological meaning is unclear. To elucidate this, we examined the relationship between the FAB score and three key imaging biomarkers: gray matter volume, amyloid-beta (Aβ) deposition, and glucose metabolism.
Twenty Aβ- and tau-positive aMCI-AD patients and age-matched controls underwent structural magnetic resonance imaging and positron emission tomography with [C]PiB and [F]FDG. Voxel-based morphometry and statistical parametric mapping analyses were performed to elucidate the relationships between FAB scores and regional gray matter volume, [C]PiB uptake for Aβ deposition, and [F]FDG uptake for glucose metabolism.
FAB scores were significantly lower in aMCI-AD than in controls (p < 0.001). In aMCI-AD, FAB was significantly correlated with right inferior frontal gray matter volume and right medial and left middle frontal glucose metabolism (family-wise error p < 0.05). However, there was no correlation between Aβ deposition and FAB (family-wise error p < 0.05).
The decreased FAB score is linked more with frontal-lobe neurodegeneration than with Aβ pathology in aMCI-AD. The FAB could be an early marker for neurodegeneration related to frontal-lobe executive dysfunction.
额叶评估量表（FAB）被广泛用于评估由阿尔茨海默病导致的遗忘型轻度认知障碍（aMCI-AD）患者的执行功能障碍，但其神经生物学意义尚不清楚。为阐明这一点，我们研究了FAB评分与三种关键成像生物标志物之间的关系：灰质体积、淀粉样β蛋白（Aβ）沉积和葡萄糖代谢。
20例Aβ和tau蛋白呈阳性的aMCI-AD患者及年龄匹配的对照组接受了结构磁共振成像以及使用[C]PiB和[F]FDG的正电子发射断层扫描。进行基于体素的形态学测量和统计参数映射分析，以阐明FAB评分与区域灰质体积、用于Aβ沉积的[C]PiB摄取以及用于葡萄糖代谢的[F]FDG摄取之间的关系。
aMCI-AD患者的FAB评分显著低于对照组（p < 0.001）。在aMCI-AD患者中，FAB与右侧额下回灰质体积以及右侧内侧和左侧额中回葡萄糖代谢显著相关（家族性错误率p < 0.05）。然而，Aβ沉积与FAB之间无相关性（家族性错误率p < 0.05）。
在aMCI-AD中，FAB评分降低更多地与额叶神经变性有关，而非与Aβ病理改变有关。FAB可能是与额叶执行功能障碍相关的神经变性的早期标志物。
